Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Biofourmis and Chugai Pharma partner to develop an objective measure of pain

By Brian Buntz | March 4, 2023

Biofourmis/ChugaiChugai Pharma (TYO:4519) and privately-held remote patient monitoring firm Biofourmis are continuing a collaboration to develop digital technologies to objectively measure and manage pain in endometriosis patients.

In endometriosis, the lining of a uterus grows outside the womb. The condition can also affect the ovaries and fallopian tubes. The disease affects approximately 10% of women of reproductive age. Stabbing pelvic pain is a common endometriosis symptom.

In general, physicians have traditionally relied on subjective measures to gauge pain. One common system, for instance, asks patients to rate their pain on a scale from 0 to 10. The Wong-Baker Faces Pain Rating Scale is similar, including pain scales using even numbers but also incorporating smiling and frowning faces.

While such scales are valuable, they are highly subjective, and patients’ personal experience and cultural background can sway their answers.

Chugai and Biofourmis have been collaborating for the past two years to come up with an objective pain measure for endometriosis.

The companies plan to use biosensors and AI algorithms to measure pain. They will validate the results in a global observational study focused on more than 120 participants with endometriosis.

Chugai has an investigational anti-IL-8 recycling antibody to treat endometriosis pain known as AMY109. In developing AMY109, Chugai will make use of Biofourmis’ technology combining remote monitoring with predictive analytics. The technology, based on Biofourmis’ Biovitals analytics engine, was designed to offer digital therapy in conjunction with medication.

Biofourmis’ technology to manage endometriosis-related pain in an outpatient setting will incorporate a clinical-grade wearable biosensor to capture physiological biomarkers. It will also include a companion app with a gamification feature to foster patient engagement and monitor symptoms. In addition, the system will use AI to quantify pain continuously by analyzing physiological biomarkers. It will also feature a web dashboard so clinicians can remotely review the data and intervene if necessary.

Other researchers have explored various techniques to quantify pain using fMRI and EEG, biomarkers and devices that can stimulate the pain response.

In 2020, Chugai and Biofourmis announced their plans to develop an objective assessment of pain based on digital technology.

In their most recent announcement, the two companies said their partnership would focus on the continued development of objective pain measurement related to endometriosis. It also includes continued work on a platform that uses real-world data to measure pain and support patient care. In addition, in the agreement, Biofourmis will also provide virtual specialty care delivery for U.S. endometriosis patients in the U.S. Finally, the most recent partnership encompasses the analysis of data collected during R&D and post-marketing activities of AMY109.

In late February, Chugai announced the publication of a non-clinical study in Science Translational Medicine that showed that AMY109 helped reduce inflammation and fibrosis.


Filed Under: Obstetrics & gynecology
Tagged With: Biofourmis, Chugai
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Endometriosis: An immune disease
Biomimetic digital twin ecosystem process tailored for the analysis.
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
positive pregnancy test in the hands of a girl close-up
The rise of ‘Ozempic babies’ and the uncharted territory of semaglutide in pregnancy
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room
A J&J veteran highlights listening to address overlooked maternal-fetal needs
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE